24 October, 2018
LUMEA is exhibiting at the Large Urology Group Practice Association (LUGPA) 2018 Annual Meeting November 1-3, 2018 at Fairmont Chicago Millennium Park, Chicago, Illinois.
At the meeting, LUMEA is debuting its “Virtual Lab” which is designed to help urology groups maintain full revenue stream despite increasing reimbursement cuts. This is accomplished by providing a slide production facility for clinics and technology to aid pathologists. Learn more about this model by contacting a LUMEA representative.
Co-exhibiting with Strand Diagnostics, LUMEA is also promoting Strand Diagnostics’ patented know error® system, which includes a no-cost prostate biopsy collection kit that incorporates DNA Specimen Provenance Assay (DSPA) to confirm that surgical biopsy samples being evaluated are free from contamination and belong exclusively to the diagnosed patient.
Strand Diagnostics is providing LUMEA’s BxBoards™ in the no-cost kit. The BxBoard is a new specimen collection device that holds up to 6 tissue to preserve orientation and reduce core fragmentation.
Find LUMEA’s booth to learn about more of its digital technology for urologists, labs, and pathologists and how it can improve their workflow, costs, and quality of patient care.
This year is the 10th annual meeting of LUGPA. The theme is "Preserving our Future Through Innovation." The meeting includes two exhibit days, urology workshops, breakout sessions, and one continuing medical education (CME) course.
LUMEA’s mission is to standardize and improve cancer diagnostics. It developed the first integrated biopsy-to-digital diagnostic platform that improves tissue handling, modernizes the pathology process, and enables the commercialization of diagnostic artificial intelligence. This Lehi, Utah-based company was founded in 2014 by Dr. Matthew O. Leavitt, a Stanford-trained pathologist.
Stand Diagnostics, Inc.
Since 2008, Strand Diagnostics, privately owned and located in Indianapolis, Indiana, has focused on medical DNA testing and maintains its CLIA, NYS, as well as several other state accreditations. Strand developed the patented know error® system and the UroSeq™ prostate cancer gene panel (which utilizes the germline DNA collected from buccal swabs as part of the Know Error kit.).